Up to now, a large number of HPV therapeutic vaccines have been
developed targeting E6 and E7 oncoproteins including peptide/protein-based vaccines,
live vector vaccines, cell-based vaccines and nucleic acid-based vaccines; each with
advantages and disadvantages. These vaccines control HPV infection through cellmediated
immunity in preclinical and clinical trials, e.g., adoptive T-cell therapy in
patients with advanced cervical cancer and/or DNA-based vaccine in HPV-16 or HPV-
18 positive CIN clinical trials. In this chapter, the potential use of therapeutic vaccines
as safe and effective pharmacological tools in cervical diseases will be explained,
focusing on vaccines that have been tested in clinical trials.
Keywords: HPV, Immunogenicity, Safety , Therapeutic vaccine.
